Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities C Hu, J Yang, Z Qi, H Wu, B Wang, F Zou, H Mei, J Liu, W Wang, Q Liu MedComm 3 (3), e161, 2022 | 168 | 2022 |
Inhibition of USP10 induces degradation of oncogenic FLT3 EL Weisberg, NJ Schauer, J Yang, I Lamberto, L Doherty, S Bhatt, ... Nature chemical biology 13 (12), 1207-1215, 2017 | 111 | 2017 |
Epigenetic regulator CXXC5 recruits DNA demethylase Tet2 to regulate TLR7/9-elicited IFN response in pDCs S Ma, X Wan, Z Deng, L Shi, C Hao, Z Zhou, C Zhou, Y Fang, J Liu, ... Journal of Experimental Medicine 214 (5), 1471-1491, 2017 | 104 | 2017 |
Th17 cells in autoimmune diseases L Han, J Yang, X Wang, D Li, L Lv, B Li Frontiers of medicine 9, 10-19, 2015 | 90 | 2015 |
Identification of the E3 deubiquitinase ubiquitin-specific peptidase 21 (USP21) as a positive regulator of the transcription factor GATA3 J Zhang, C Chen, X Hou, Y Gao, F Lin, J Yang, Z Gao, L Pan, L Tao, ... Journal of Biological Chemistry 288 (13), 9373-9382, 2013 | 78 | 2013 |
Cutting edge: ubiquitin-specific protease 4 promotes Th17 cell function under inflammation by deubiquitinating and stabilizing RORγt J Yang, P Xu, L Han, Z Guo, X Wang, Z Chen, J Nie, S Yin, M Piccioni, ... The Journal of Immunology 194 (9), 4094-4097, 2015 | 66 | 2015 |
The E3 deubiquitinase USP17 is a positive regulator of retinoic acid-related orphan nuclear receptor γt (RORγt) in Th17 cells L Han, J Yang, X Wang, Q Wu, S Yin, Z Li, J Zhang, Y Xing, Z Chen, ... Journal of Biological Chemistry 289 (37), 25546-25555, 2014 | 62 | 2014 |
Mixed lineage leukemia 5 (MLL5) protein stability is cooperatively regulated by O-GlcNac transferase (OGT) and ubiquitin specific protease 7 (USP7) X Ding, W Jiang, P Zhou, L Liu, X Wan, X Yuan, X Wang, M Chen, J Chen, ... PloS one 10 (12), e0145023, 2015 | 58 | 2015 |
Molecular mechanisms underlying the regulation and functional plasticity of FOXP3+ regulatory T cells Y Gao, F Lin, J Su, Z Gao, Y Li, J Yang, Z Deng, B Liu, A Tsun, B Li Genes & Immunity 13 (1), 1-13, 2012 | 53 | 2012 |
Reciprocal regulation of RORγt acetylation and function by p300 and HDAC1 Q Wu, J Nie, Y Gao, P Xu, Q Sun, J Yang, L Han, Z Chen, X Wang, L Lv, ... Scientific reports 5 (1), 16355, 2015 | 52 | 2015 |
TRAF5-mediated Lys-63-linked polyubiquitination plays an essential role in positive regulation of RORγt in promoting IL-17A expression X Wang, J Yang, L Han, K Zhao, Q Wu, L Bao, Z Li, L Lv, B Li Journal of Biological Chemistry 290 (48), 29086-29094, 2015 | 47 | 2015 |
The deubiquitinase USP44 promotes Treg function during inflammation by preventing FOXP3 degradation J Yang, P Wei, J Barbi, Q Huang, E Yang, Y Bai, J Nie, Y Gao, J Tao, Y Lu, ... EMBO reports 21 (9), e50308, 2020 | 46 | 2020 |
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU‐285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies E Weisberg, C Meng, AE Case, M Sattler, HL Tiv, PC Gokhale, ... British journal of haematology 187 (4), 488-501, 2019 | 34 | 2019 |
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase EL Weisberg, A Puissant, R Stone, M Sattler, SJ Buhrlage, J Yang, ... Oncotarget 8 (32), 52026, 2017 | 26 | 2017 |
Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia E Weisberg, C Meng, AE Case, HL Tiv, PC Gokhale, SJ Buhrlage, J Yang, ... Journal of Cellular and Molecular Medicine 24 (5), 2968-2980, 2020 | 23 | 2020 |
Inhibition of the deubiquitinase USP10 induces degradation of SYK J Yang, C Meng, E Weisberg, A Case, I Lamberto, RS Magin, S Adamia, ... British Journal of Cancer 122 (8), 1175-1184, 2020 | 19 | 2020 |
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2 J Yang, EL Weisberg, X Liu, RS Magin, WC Chan, B Hu, NJ Schauer, ... Leukemia 36 (1), 210-220, 2022 | 13 | 2022 |
Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies H Mei, H Wu, J Yang, B Zhou, A Wang, C Hu, S Qi, Z Jiang, F Zou, ... Signal Transduction and Targeted Therapy 8 (1), 18, 2023 | 8 | 2023 |
Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2 J Yang, EL Weisberg, S Qi, W Ni, H Mei, Z Wang, C Meng, S Zhang, ... Leukemia 36 (4), 1048-1057, 2022 | 6 | 2022 |
Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2 Y Xue, H Mei, Y Chen, JD Griffin, Q Liu, E Weisberg, J Yang MedComm 4 (3), e254, 2023 | 4 | 2023 |